Other
Neonatal Jaundice
3
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Neonatal Jaundice is an early-stage landscape with 3 programs across 3 companies. The most active players are Alnylam Pharmaceuticals, Jagotec, Amgen. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Approved
No programs
Analysis
Trial Status
4
clinical trials
Not yet recruiting2 · 50%
Completed2 · 50%
Clinical Trials
Trial Activity
Comparison of Effects of Fenofibrate Adjuvant Therapy Versus Conventional Phototherapy in Neonatal Jaundice.
Not yet recruiting·—·Phase 2/3·NCT06346743·156 enrolled
Effect of Vitamin D Supplementation as Adjuvant Therapy in Neonatal Jaundice in Combination With Phototherapy
Completed·—·N/A·NCT06650293·100 enrolled
Role of Fenofibrate in Neonatal Jaundice
Completed·—·Phase 4·NCT06451900·75 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)